Business
Viveve(R) Announces Pricing of $13.5 Million Public Offering of Shares of Common Stock and NASDAQ Uplisting
Viveve(R) Announces Pricing of $13.5 Million Public Offering of Shares of Common Stock and NASDAQ Uplisting.
About this update from Viveve Medical, Inc.
[{"type":"text","content":"\nViveve(R) Announces Pricing of $13.5 Million Public Offering of Shares of Common Stock and NASDAQ Uplisting\n\nViveve(R) Announces Pricing of $13.5 Million Public Offering of Shares of Common Stock and NASDAQ Uplisting\n\nSUNNYVALE, CA--(Marketwired - June 14, 2016) - Viveve Medical, Inc. (\"Viveve\") (NASDAQ: VIVE) (OTCQB: VIVMF), a medical technology company focused on women's health, today announced the pricing of an underwritten public offering of 2,700,000 shares of its common stock at a price to the public of $5.00 per share, for gross proceeds of approximately $13.5 million. The net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $12.2 million. Viveve has granted the underwriters a 45-day option to purchase up to an additional 405,000 shares of common stock in connection with the public offering. Subject to customary conditions, Viveve expects to close the sale of its common stock on or about June 17, 2016.Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. and Craig-Hallum Capital Group LLC are the joint book-running managers of the offering and Maxim Group LLC is acting as co-manager.This announcement shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The securities described above are being offered by Viveve pursuant to a registration statement previously filed and declared effective by the U.S. Securities and Exchange Commission. The offering will be made only by means of a prospectus, copies of which can be obtained from Ladenburg Thalmann & Co., Inc., 570 Lexington Avenue, 11th Fl., New York, NY 10022, (212) 409-2000 or by accessing the SEC's website, www.sec.gov.About ViveveViveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity that can re...